title: [Community-acquired urinary tract infections in 15 to 65 years old female patients in France. Susceptibility of E. coli according to history: AFORCOPI-BIO network 2003].
abstract: OBJECTIVE
  A multicenter study was implemented in order to determine the distribution and antibiotic susceptibility patterns of strains isolated from 15 to 65 year old female patients with community-acquired urinary tract infections.
  
  
  METHODS
  From October to December 2003, 11 French private laboratories consecutively collected 420 clinical strains with medical data. Minimal inhibitory concentrations of antibiotics on E. coli were determined using the agar dilution method in a coordinating center and interpretation followed the recommendations of the Comité de l'antibiogramme de la Société française de microbiologie.
  
  
  RESULTS
  Escherichia coli was the most prevalent pathogen (80%) followed by Proteus mirabilis (4%), Klebsiella spp (2%), other Enterobacteriaceae (4%), Enterococcus spp (3%), Staphylococcus aureus (2%), Staphylococcus saprophyticus (2%), and Streptococcus agalactiae (2%). The susceptibility of E. coli strains was 61% for amoxicillin (AMX), 93% for nalidixic acid (NAL), 97% for norfloxacin (NOR) and ciprofloxacin (CIP), 77% for cotrimoxazole (SXT), 99% for fosfomycin, gentamicin and cefotaxime. The susceptibility of E. coli was lower in case of previous treatment with beta-lactam antibiotics for AMX (84 vs 95% p=0.02) and SXT (62 vs 81% p=0.02). In the same way, previous treatment with quinolones was associated with decreased susceptibility for NAL (84 vs 95% p=0.02) and SXT (62 vs 81% p=0.02).
  
  
  CONCLUSIONS
  In 2003, fluoroquinolones, third generation cephalosporins, aminoglycosides, and fosfomycin kept a good activity on E. coli collected from community-acquired urinary tract infections in 15 to 65 years old female patients in France.
authors.affiliation: LABM Claude-Bernard, 39, rue Claude-Bernard 75005 Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: de Mouy
authors.forename: R
authors.initials: R
authors.lastname: Fabre
authors.forename: J-D
authors.initials: JD
authors.lastname: Cavallo
authors.forename: J-P
authors.initials: JP
authors.lastname: Arzouni
authors.forename: M
authors.initials: M
authors.lastname: Baynat
authors.forename: A
authors.initials: A
authors.lastname: Bicart-See
authors.forename: J-L
authors.initials: JL
authors.lastname: Berges
authors.forename: J-P
authors.initials: JP
authors.lastname: Bouilloux
authors.forename: J-L
authors.initials: JL
authors.lastname: Galinier
authors.forename: E
authors.initials: E
authors.lastname: Garrabé
authors.forename: P
authors.initials: P
authors.lastname: Gontier
authors.forename: N
authors.initials: N
authors.lastname: Grillet
authors.forename: J-P
authors.initials: JP
authors.lastname: Lepargneur
authors.forename: I
authors.initials: I
authors.lastname: Naepels
authors.forename: G
authors.initials: G
authors.lastname: Payro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects*; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011446:Prospective Studies; D014552:Urinary Tract Infections / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents